# India Recombinant Vaccines Market > India Recombinant Vaccines Market Research Report By Product (Subunit Recombinant, Attenuated Recombinant Vaccines), By Disease (Cancer, Pneumococcal Disease, Hepatitis B, DPT) and By End-Users (Pediatrics, Adults, Veterinary) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 16.56% - **2024:** $ 18 Million - **2025:** $ 20.98 Million - **2035:** $ 97.12 Million - **Key Players:** Pfizer (US), Moderna (US), Sanofi (FR), Merck (US), GSK (GB), Novartis (CH), Bayer (DE), AstraZeneca (GB), Boehringer Ingelheim (DE) **Report ID:** MRFR/Pharma/54247-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/india-recombinant-vaccines-market-56013 --- ## Market Summary ## **India Recombinant Vaccines Market Overview** As per MRFR analysis, the India Recombinant Vaccines Market Size was estimated at 11.6 (USD Million) in 2024.The India Recombinant Vaccines Market Industry is expected to grow from 14.4(USD Million) in 2025 to 57.6 (USD Million) by 2035. The India Recombinant Vaccines Market CAGR (growth rate) is expected to be around 13.431% during the forecast period (2025 - 2035). **Key India Recombinant Vaccines Market Trends Highlighted** The India Recombinant Vaccines Market is experiencing significant growth driven by several key market drivers. The increasing prevalence of infectious diseases, alongside the rise in awareness about vaccination, is pushing more individuals towards seeking vaccines derived from recombinant technology. Additionally, government initiatives aimed at enhancing vaccination coverage, particularly in rural and underserved areas, are facilitating easier access to these vaccines. These efforts are supported by the Indian government's focus on public health, as reflected in national vaccination programs and campaigns that emphasize preventive healthcare.  As the biotechnology sector continues to advance, there are numerous opportunities to be explored in the realm of recombinant vaccines in India. The collaboration between public and private sectors can lead to innovative vaccine development, ensuring that vaccines are not only effective but also affordable. Furthermore, the growing emphasis on research and development within the pharmaceutical industry can enhance the production of multiple recombinant vaccines, addressing various health challenges faced by the population.  Recent trends in the India Recombinant Vaccines Market highlight a shift towards personalization and precision medicine.As more research is conducted, vaccines are being tailored to address specific demographic needs, potentially improving immunogenic responses. The surge in investments in healthcare infrastructure and biotech innovations, driven by both government support and private sector investment, is paving the way for new products in the market. These trends, combined with a focus on 'Make in India' initiatives, are shaping the future of the recombinant vaccine landscape in the country, making India a pivotal player in the global vaccine ecosystem. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **India Recombinant Vaccines Market Drivers** **Increasing Government Support for Vaccine Development** The Government of India has been actively investing in the health sector, particularly in the development of vaccines. The Indian government allocated approximately 2.1% of its gross domestic product (GDP) to healthcare in 2022, reflecting its commitment to enhancing the healthcare infrastructure. This financial backing is critical as it supports the Research and Development (R&D) initiatives for recombinant vaccines.  Organizations like the Indian Council of Medical Research (ICMR) and the Department of Biotechnology (DBT) are pivotal in fostering an innovation-driven environment.Their promotion of collaborative projects with private sectors and academic institutions not only accelerates the pace of vaccine development but also positions India as a global hub for vaccine manufacturing. This support is particularly vital in a post-COVID-19 world where there is a pivotal focus on vaccine accessibility and efficacy, thus driving growth in the India Recombinant Vaccines Market Industry. **Rising Incidence of Infectious Diseases** There has been a notable rise in the prevalence of infectious diseases in India, fueling the demand for effective vaccines. For instance, the Ministry of Health and Family Welfare reports that vaccine-preventable diseases, such as hepatitis B and tuberculosis, still account for significant mortality rates. The Global Burden of Disease Study indicated that in 2020, approximately 1.5 million people in India lost their lives due to various communicable diseases. The India Recombinant Vaccines Market Industry is driven in great part by this figure, which also motivates public and commercial sectors to increase vaccine development and manufacturing investment. Through the creation of recombinant vaccines, established companies like Bharat Biotech and the Serum Institute of India lead the front stage in tackling these health issues. **Technological Advancements in Vaccine Development** The field of vaccine technology has seen rapid advancements that contribute significantly to the growth of the India Recombinant Vaccines Market. Innovations such as synthetic biology and advanced protein engineering are streamlining the vaccine development process, making it faster and more efficient.  According to the Biotechnology Industry Research Assistance Council, the biotechnology sector in India is projected to reach USD 150 billion by 2025, which encapsulates significant investments in vaccine technologies.Companies like Genova Biopharma and Zydus Cadila are leveraging these advancements, enabling them to produce high-quality vaccines at a lower cost. Such technological prowess not only improves the effectiveness of recombinant vaccines but also enhances their accessibility to the Indian population, thus playing a critical role in market expansion. **Growing Public Awareness about Vaccination** Public awareness regarding the importance of vaccination is escalating in India, particularly after the COVID-19 pandemic. The Communication for Health program initiated by the Ministry of Health and Family Welfare has significantly contributed to educating the masses on the benefits of vaccines. Reports suggest that around 80% of urban Indians are now aware of the significance of vaccinations against preventable diseases.  This increased awareness has cultivated a proactive attitude towards immunization, driving the demand for recombinant vaccines.Organizations such as the Bill and Melinda Gates Foundation are also investing in awareness campaigns, further facilitating public engagement in vaccination programs. This heightened awareness ultimately fuels the growth of the India Recombinant Vaccines Market Industry as more individuals seek vaccination options. **India Recombinant Vaccines Market Segment Insights** **Recombinant Vaccines Market Product Insights** The India Recombinant Vaccines Market is becoming a pivotal part of the healthcare landscape, reflecting the advancements in biopharmaceutical technology and public health initiatives. The Product segment of this market shows a promising trajectory driven by the steady rise in vaccine-preventable diseases and the growing awareness of immunization. Among the various categories, Subunit Recombinant Vaccines hold significant importance as they utilize only essential antigens, leading to a strong immune response while minimizing side effects. This characteristic position Subunit Recombinant Vaccines as a suitable option for individuals with compromised immune systems, making them a preferred choice in India’s diverse population. Alongside this, Attenuated Recombinant Vaccines are noteworthy for their ability to induce lasting immunity by replicating the pathogen in a weakened form. This technology is frequently adopted in national immunization programs as it offers the potential for robust and long-lasting immune responses with just a single dose in many scenarios. The emphasis on achieving higher vaccination coverage rates in India has catalyzed Research and Development endeavors focused on these product innovations. Public health organizations are keen on leveraging the benefits of recombinant vaccination technologies to address emerging infectious diseases and to develop targeted vaccines against prevalent health issues in the country. The alignment of these products with government health policies strengthens their market presence significantly. Various stakeholders, including governmental and non-governmental entities, contribute to intensifying the focus on these vaccine technologies, driven by the collective goal of enhancing public health security. The increasing incidence of diseases like Hepatitis B, Dengue, and COVID-19 accentuates the demand for effective vaccines, emphasizing the role of both Subunit and Attenuated Recombinant Vaccines in combating these health challenges. Furthermore, the growing trend of personalized medicine in India, alongside global collaborations in vaccine development, is reshaping the landscape of the Recombinant Vaccines Market. Ultimately, as India seeks to strengthen its immunization framework, it can be anticipated that both Subunit and Attenuated Recombinant Vaccines will continue to play critical roles in achieving the nation’s health objectives and improving overall public health outcomes. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Recombinant Vaccines Market Disease Insights** The Disease segment of the India Recombinant Vaccines Market is experiencing notable growth as awareness around vaccination increases and the burden of infectious diseases and cancers continues to rise. Cancer remains a significant concern due to its high prevalence, with a growing population in India increasingly facing various oncological challenges. Pneumococcal diseases pose a public health threat, particularly among children, making effective vaccines vital for reducing morbidity and mortality rates.  Hepatitis B remains endemic in certain regions of India, prompting urgent demand for preventive vaccinations.The DPT (Diphtheria, Pertussis, Tetanus) vaccine is crucial for children's immunization programs, contributing significantly to public health by preventing life-threatening diseases. The ongoing focus on vaccination drives, supported by governmental health initiatives, has the potential to drive advancements in recombinant vaccine technologies, aligning with India's healthcare objectives and enhancing access to life-saving interventions for its vast population. Overall, these factors suggest a dynamic landscape for the India Recombinant Vaccines Market, driven by the urgent need for effective vaccine solutions against these diseases. **Recombinant Vaccines Market End-User Insights** The India Recombinant Vaccines Market is poised for growth with distinct contributions from various end-users, including Pediatrics, Adults, and Veterinary sectors. The Pediatrics segment is critical, given the increasing vaccination coverage for children mandated by national health programs aimed at preventing infectious diseases that affect childhood mortality. The Adult segment is significant as well, fueled by the rising awareness of preventive healthcare and the introduction of vaccines against diseases such as influenza and viral hepatitis.Furthermore, the Veterinary segment is gaining traction with an increasing focus on animal health and welfare, given that vaccination can prevent outbreaks that affect livestock and pets, thereby supporting food security and public health.  This segmentation indicates a diversified approach towards vaccination, addressing specific health needs and driving the demand for innovative recombinant vaccines across the region. The India Recombinant Vaccines Market is thus shaped by the interplay of these end-user dynamics, presenting opportunities for growth and development in the healthcare landscape.With government initiatives and partnerships fostering research and development, the market exhibits a robust potential to cater to the diverse population's requirements while mitigating health risks effectively. **India Recombinant Vaccines Market Key Players and Competitive Insights** The India Recombinant Vaccines Market is characterized by significant competition among various pharmaceutical giants, reflecting an expanding landscape marked by innovation and strategic partnerships. As the demand for vaccines rises, driven by health concerns, including infectious diseases and public health initiatives, companies are increasingly focusing on recombinant technology to develop more effective and safe vaccines. This market is shaped by advancements in biotechnology that enable the production of vaccines that not only provide immunization but also address multiple health ailments. The dynamic interplay between established firms and emerging biotech companies is also contributing to a diverse portfolio of vaccine offerings in India, creating opportunities for strategic collaborations, mergers, and acquisitions.  Understanding the strengths, market presence, and product differentiation strategies of key players is essential for gaining insights into the competitive landscape of the India Recombinant Vaccines Market.Pfizer has a notable footprint in the India Recombinant Vaccines Market, capitalizing on its extensive research capabilities and established reputation for quality and innovation. The company's strengths lie in its comprehensive product offerings, which include vaccines developed using recombinant technology aimed at combating various infectious diseases prevalent in India. Pfizer prioritizes strategic partnerships and collaborations with local research institutions, enabling faster development and distribution of vaccines tailored to regional health needs. The company’s robust supply chain capabilities and regulatory expertise allow it to navigate the complexities of the Indian market efficiently, ensuring that its products maintain accessibility and affordability.  Furthermore, Pfizer's ongoing investment in clinical trials and research has positioned it to leverage emerging opportunities while reinforcing its position as a leader in vaccine development in India.Merck plays a significant role in the India Recombinant Vaccines Market, backed by its commitment to research and development of innovative healthcare solutions. The company is known for key products that utilize recombinant technology, providing effective immunization against various diseases. With a strong market presence, Merck has established collaborations with government entities and healthcare organizations, enhancing its distribution network across India. The company's strengths also include its focus on education and awareness programs aimed at increasing vaccination rates and public understanding of infectious diseases. Additionally, Merck has been active in mergers and acquisitions that bolster its product pipeline and expand its operational capabilities within the region. By aligning its strategies with the needs of the Indian healthcare landscape, Merck continues to strengthen its position and foster growth within the recombinant vaccines sector. **Key Companies in the India Recombinant Vaccines Market Include:** - Pfizer - Merck - Abbott - Spilva - Moderna - Novavax - Zydus Cadila - Bharat Biotech - Sanofi - Indian Immunologicals - Veryan - Serum Institute of India - AstraZeneca - GSK - Biological E **India Recombinant Vaccines Market Industry Developments** The India Recombinant Vaccines Market is witnessing significant developments. In June 2023, Zydus Cadila received approval for its recombinant vaccine targeting the latest COVID-19 variant, indicating the ongoing evolution of vaccine technology in response to emerging health challenges. Bharat Biotech has announced advancements in its recombinant vaccine pipeline, focusing on biopharmaceuticals and other infectious diseases.  In August 2023, Serum Institute of India revealed plans to expand its output capacity, capitalizing on the high demand for vaccines, particularly in rural areas. Notably, the market has seen a valuation surge, with Pfizer and Merck reporting substantial growth in their Indian operations, reflecting an increasing market focus on innovative vaccine solutions. In terms of mergers and acquisitions, no significant deals have been publicly announced in recent months among key players like Moderna, Sanofi, or AstraZeneca specifically targeting the Indian recombinant vaccine space.  Over the past 2-3 years, the market has been influenced heavily by the COVID-19 pandemic, leading to enhanced investments in Research and Development efforts across multiple companies, including Indian Immunologicals and Biological E, reaffirming India's strategic position in the global vaccine landscape. **India Recombinant Vaccines Market Segmentation Insights** **Recombinant Vaccines Market Product Outlook** - Subunit Recombinant - Attenuated Recombinant Vaccines **Recombinant Vaccines Market Disease Outlook** - Cancer - Pneumococcal Disease - Hepatitis B - DPT **Recombinant Vaccines Market End-Users Outlook** - Pediatrics - Adults - Veterinary ## Market Drivers ### Rising Healthcare Expenditure Rising healthcare expenditure in India is a substantial driver for the recombinant vaccines market. The government has committed to increasing healthcare spending, aiming to reach 2.5% of GDP by 2025. This financial commitment is likely to enhance the availability and accessibility of vaccines, including recombinant types. As healthcare budgets expand, there is a growing focus on preventive healthcare measures, including vaccination programs. The recombinant vaccines market stands to gain from this shift, as increased funding allows for broader immunization campaigns and the introduction of new vaccines. Consequently, the market is expected to witness robust growth, driven by enhanced healthcare infrastructure and increased public health initiatives. ### Growing Public-Private Partnerships The emergence of public-private partnerships (PPPs) is significantly impacting the recombinant vaccines market. These collaborations between government agencies and private companies enhance resource allocation and expertise sharing, leading to more efficient vaccine development processes. In India, several successful PPP initiatives have been established to address public health challenges, particularly in vaccine research and distribution. Such partnerships not only facilitate funding but also promote knowledge exchange, which is crucial for the advancement of recombinant vaccine technologies. As these collaborations continue to flourish, the recombinant vaccines market is expected to benefit from increased innovation and improved access to vaccines across diverse populations. ### Investment in Biotechnology Research Investment in biotechnology research is a pivotal factor influencing the recombinant vaccines market. India has emerged as a hub for biopharmaceutical research, with the government and private entities allocating substantial funds towards vaccine development. In recent years, the biotechnology sector has attracted investments exceeding $1 billion, reflecting a growing recognition of the importance of innovative healthcare solutions. This influx of capital facilitates the advancement of recombinant vaccine technologies, enabling the development of safer and more effective vaccines. As research institutions collaborate with pharmaceutical companies, the recombinant vaccines market is poised for significant growth, driven by the introduction of novel vaccines that address both existing and emerging infectious diseases. ### Rising Incidence of Infectious Diseases The increasing prevalence of infectious diseases in India is a critical driver for the recombinant vaccines market. With a population exceeding 1.4 billion, the country faces significant health challenges, including outbreaks of diseases such as dengue, hepatitis, and influenza. The demand for effective vaccines is likely to surge as healthcare authorities strive to mitigate these health threats. According to recent estimates, the burden of infectious diseases accounts for approximately 30% of total disease burden in India. This scenario compels the government and private sectors to invest in the development and distribution of recombinant vaccines, thereby propelling market growth. The recombinant vaccines market is expected to expand as healthcare providers seek innovative solutions to combat these diseases, ensuring better public health outcomes. ### Regulatory Support and Streamlined Approval Processes Regulatory support plays a vital role in shaping the recombinant vaccines market. The Indian government has implemented streamlined approval processes to expedite the development and commercialization of vaccines. Initiatives such as the 'Make in India' campaign encourage local manufacturing of vaccines, reducing dependency on imports. The Central Drugs Standard Control Organization (CDSCO) has also introduced guidelines that facilitate faster clinical trials and approvals for recombinant vaccines. This regulatory environment fosters innovation and encourages investment in vaccine development. As a result, the recombinant vaccines market is likely to experience accelerated growth, with more products entering the market to meet the increasing demand for immunization. ## Future Outlook The [Recombinant Vaccines Market](https://www.marketresearchfuture.com/reports/recombinant-vaccines-market-6130) is projected to grow at a 16.56% CAGR from 2025 to 2035, driven by technological advancements, increasing healthcare investments, and rising disease prevalence. **New opportunities:** - Development of personalized recombinant vaccines for niche markets. - Expansion of distribution networks to rural healthcare facilities. - Investment in R&D for next-generation vaccine platforms. By 2035, the recombinant vaccines market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Subunit Recombinant Vaccines (Largest) vs. Vector Recombinant Vaccines (Fastest-Growing) In the India recombinant vaccines market, subunit recombinant vaccines hold the largest share due to their high safety profile and effectiveness in providing targeted immune responses. These vaccines are increasingly preferred in both human and veterinary applications, leading to significant market penetration. Vector recombinant vaccines are gaining traction as well, driven by advancements in genetic engineering and their ability to induce strong immune responses across various populations. Growth trends indicate that while subunit recombinant vaccines dominate the market, vector recombinant vaccines are emerging rapidly as a preferred choice for future vaccine development. Factors propelling this growth include the necessity for innovative healthcare solutions, increasing investments in biotechnology, and growing public awareness about advanced vaccination methodologies that enhance disease prevention. Subunit (Dominant) vs. Vector (Emerging) Subunit recombinant vaccines are characterized by their composed proteins that elicit robust immune responses without introducing live pathogens, thus minimizing side effects. This safety and efficacy have made them a mainstay in immunization programs. On the other hand, vector recombinant vaccines employ modified viruses or bacteria as delivery systems to present antigens to the immune system. Their emergent popularity arises from their versatility and ability to provoke strong and lasting immunity, crucial in combating infectious diseases effectively in diverse populations. ### By Disease: Pneumococcal Disease (Largest) vs. Cancer (Fastest-Growing) The India recombinant vaccines market showcases a diverse distribution among its disease segments. Pneumococcal Disease currently leads the segment with significant market share, demonstrating strong consumer adoption and awareness. Following closely are Cancer and Hepatitis B vaccines, which have also established solid positions due to heightened healthcare initiatives and vaccination programs. The Influenza and DPT vaccines contribute to the market but are comparatively smaller in terms of share. Growth trends within the segment are driven by increasing incidences of diseases, rising healthcare expenditure, and government-backed vaccination programs. The Cancer vaccine segment is witnessing rapid growth, attributed to innovative research and development strategies. As concerns about infectious diseases continue to rise, Pneumococcal Disease remains a dominant focus, supported by widespread immunization campaigns across the region, enhancing public health outcomes. Pneumococcal Disease: Dominant vs. Cancer: Emerging Pneumococcal Disease vaccines are the cornerstone of the India's vaccination strategy, boasting the largest share within the segment. These vaccines are crucial in preventing severe infections and are extensively supported by healthcare policies aimed at improving community health. On the other hand, Cancer vaccines, though currently smaller in market size, are rapidly emerging due to increased awareness and funding in oncology research. The push for early cancer detection and prevention strategies is fostering growth, with innovative cancer vaccines gaining traction. Both segments are crucial in addressing public health challenges, with Pneumococcal vaccines providing a strong foundation and Cancer vaccines representing the future potential. ### By End-User: Hospitals & Clinics (Largest) vs. Poultry (Fastest-Growing) The market share distribution among the end-user segments of the India recombinant vaccines market shows that hospitals and clinics hold the largest share, driven by the high demand for vaccines in healthcare settings. Following closely are veterinary applications, as livestock and poultry segments are increasingly adopting recombinant vaccines due to their effectiveness. Other segments such as pediatrics and adults also contribute significantly but at a smaller scale. Growth trends indicate a positive trajectory for the India recombinant vaccines market, particularly for poultry and veterinary applications, which are recognized as the fastest-growing sectors. This growth is fueled by increased awareness of animal health, government initiatives promoting vaccine use, and advancements in vaccine technology. Additionally, growing consumer demand for safe and healthy food products plays a critical role in shaping this market segment. Hospitals & Clinics (Dominant) vs. Poultry (Emerging) The hospitals and clinics segment is characterized by its dominant position, primarily due to the infrastructure and resources available for vaccine administration and patient care. This segment benefits from established healthcare networks and a consistent demand for vaccines among patients. On the other hand, the poultry segment is emerging rapidly as a crucial area for recombinant vaccine application. With the rise of poultry diseases and the need for preventive measures, the sector is experiencing accelerated growth. Poultry farmers are increasingly investing in advanced vaccine solutions to enhance flock health and productivity, making it a vital contributor to overall market expansion. ## Competitive Benchmarking The recombinant vaccines market in India is characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on regional expansion. Key players such as Pfizer (US), Moderna (US), and Sanofi (FR) are actively shaping the market through their distinct operational strategies. Pfizer (US) emphasizes innovation in vaccine development, particularly in mRNA technology, while Moderna (US) focuses on expanding its manufacturing capabilities within India to enhance local production. Sanofi (FR), on the other hand, is leveraging strategic partnerships with local biotech firms to accelerate its vaccine pipeline, thereby enhancing its market presence. Collectively, these strategies contribute to a competitive environment that is increasingly focused on technological advancement and localized solutions.In terms of business tactics, companies are increasingly localizing their manufacturing processes to optimize supply chains and reduce costs. This trend is particularly evident in the moderately fragmented structure of the market, where several players vie for market share. The collective influence of these key players is significant, as they not only drive innovation but also set benchmarks for quality and efficacy in vaccine production, thereby shaping consumer trust and market dynamics. In October Pfizer (US) announced a collaboration with a leading Indian pharmaceutical company to establish a state-of-the-art manufacturing facility in Maharashtra. This strategic move is expected to enhance Pfizer's production capacity and reduce lead times for vaccine distribution across the region. The establishment of this facility underscores Pfizer's commitment to localizing its operations and responding to the growing demand for vaccines in India. In September Moderna (US) unveiled a new partnership with a prominent Indian research institution to develop next-generation recombinant vaccines targeting emerging infectious diseases. This collaboration is poised to leverage local expertise and accelerate the development timeline, reflecting Moderna's strategy to integrate regional insights into its global vaccine development framework. Such initiatives are likely to enhance Moderna's competitive edge in the Indian market. In August Sanofi (FR) expanded its existing partnership with a local biotech firm to co-develop a recombinant vaccine aimed at addressing specific regional health challenges. This strategic alliance not only strengthens Sanofi's product portfolio but also aligns with its goal of enhancing access to vaccines tailored to the Indian population. The collaboration exemplifies how strategic partnerships can facilitate innovation and market penetration. As of November current trends in the recombinant vaccines market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in vaccine development processes. Strategic alliances are playing a crucial role in shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that prioritize these elements may be better positioned to thrive in the evolving market. ## Recent News & Developments The India Recombinant Vaccines Market is witnessing significant developments. In June 2023, Zydus Cadila received approval for its recombinant vaccine targeting the latest COVID-19 variant, indicating the ongoing evolution of vaccine technology in response to emerging health challenges. Bharat Biotech has announced advancements in its recombinant vaccine pipeline, focusing on biopharmaceuticals and other infectious diseases.  In August 2023, Serum Institute of India revealed plans to expand its output capacity, capitalizing on the high demand for vaccines, particularly in rural areas. Notably, the market has seen a valuation surge, with Pfizer and Merck reporting substantial growth in their Indian operations, reflecting an increasing market focus on innovative vaccine solutions. In terms of mergers and acquisitions, no significant deals have been publicly announced in recent months among key players like Moderna, Sanofi, or AstraZeneca specifically targeting the Indian recombinant vaccine space.  Over the past 2-3 years, the market has been influenced heavily by the COVID-19 pandemic, leading to enhanced investments in Research and Development efforts across multiple companies, including Indian Immunologicals and Biological E, reaffirming India's strategic position in the global vaccine landscape. ## Report Scope | MARKET SIZE 2024 | 18.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 20.98(USD Million) | | MARKET SIZE 2035 | 97.12(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 16.56% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Pfizer (US), Moderna (US), Sanofi (FR), Merck (US), GSK (GB), Novartis (CH), Bayer (DE), AstraZeneca (GB), Boehringer Ingelheim (DE) | | Segments Covered | Type, Disease, End-User | | Key Market Opportunities | Advancements in genetic engineering enhance efficacy and safety in the recombinant vaccines market. | | Key Market Dynamics | Rising demand for innovative recombinant vaccines driven by regulatory support and technological advancements in India. | | Countries Covered | India | ## Frequently Asked Questions **Q: What is the current valuation of the India recombinant vaccines market?** A: The market valuation was $18.0 Million in 2024. **Q: What is the projected market size for the India recombinant vaccines market by 2035?** A: The projected valuation for 2035 is $97.12 Million. **Q: What is the expected CAGR for the India recombinant vaccines market during the forecast period 2025 - 2035?** A: The expected CAGR is 16.56%. **Q: Which types of recombinant vaccines are included in the market segments?** A: The market segments include subunit, attenuated, and vector recombinant vaccines. **Q: What was the market value for subunit recombinant vaccines in 2024?** A: The market value for subunit recombinant vaccines was $3.6 Million in 2024. **Q: How much is the market for attenuated recombinant vaccines projected to grow by 2035?** A: The market for attenuated recombinant vaccines is projected to reach $36.0 Million by 2035. **Q: What diseases are targeted by recombinant vaccines in the India market?** A: Diseases targeted include pneumococcal disease, cancer, hepatitis B, influenza, and DPT. **Q: What was the market value for hepatitis B vaccines in 2024?** A: The market value for hepatitis B vaccines was $4.0 Million in 2024. **Q: Which end-users are driving the demand for recombinant vaccines?** A: End-users include hospitals & clinics, pediatrics, adults, veterinary, poultry, and livestock. **Q: What was the market value for the pediatrics segment in 2024?** A: The market value for the pediatrics segment was $4.5 Million in 2024. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-recombinant-vaccines-market-56013*